<DOC>
	<DOCNO>NCT01015638</DOCNO>
	<brief_summary>This single-blind ( blind expert grader ) study enroll 25-30 healthy volunteer without facial acne . On 1 side face , subject apply 1 2 test product , clindamycin benzoyl peroxide 5 % clindamycin phosphate benzoyl peroxide 2.5 % side face remain non-treated serve control .</brief_summary>
	<brief_title>Compare Tolerance Clindamycin 1 % /Benzoyl Peroxide ( BPO ) 5 % Gel Clindamycin 1.2 % / BPO 2.5 % Topical Medications</brief_title>
	<detailed_description>This single-blind ( blind expert grader ) , parallel group , randomize , half-face study conduct one clinical site . On 1 side face , subject apply 1 2 test product , clindamycin benzoyl peroxide 5 % ) clindamycin benzoyl peroxide 2.5 % ) side face remain non-treated serve control . Approximately 25-30 male female healthy subject without facial acne , age 18 45 , randomly assign product . The eligible subject ( screen 3 day prior randomization ) qualify entered 2-week treatment phase . The once-daily application clindamycin benzoyl peroxide 5 % clindamycin phosphate benzoyl peroxide 2.5 % ) supervise site , Monday Friday week . Subjects apply study product home Saturdays Sundays record time application diary card . A blinded expert grader rate comparative product tolerance term erythema dryness week day ( exclude Saturdays Sundays ) study study product apply . Instruments used measure transepidermal water loss ( TEWL ) ass skin moisture order evaluate product mildness . Instrumentation measurement skin surface conductance utilized evaluate product performance term level skin hydration . Subjects complete questionnaire adverse event record .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Capable understand willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocol specific procedure perform . Male female subject age 18 45 year time consent . Is willing discontinue use facial product ( cleanser provide makeup razor facial shave product ) face 3 day baseline/day 0 visit use provide facial product normal makeup razor facial shave product duration study . Is willing change brand makeup razor facial shave product study . Is willing refrain use facial product face study product normal makeup razor facial shave product duration study . Able complete study comply study instruction . Sexually active female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product Female subject pregnant , try become pregnant , breast feeding . Male subject facial beard ( mustache and/or goatee acceptable ) . Is Type I diabetic . Has active chronic skin allergy . Has history acute chronic disease might interfere , increase risk study participation . Has participate facial study precede 30 day clinical study precede 14 day . Had skin cancer treatment precede 12 month . Has damage skin facial area ( eg , sunburn , tattoo , scar ) . Had medical procedure ( eg , laser resurfacing , chemical peel , plastic surgery ) facial area precede 12 month . Had cosmetic procedure ( eg , microdermabrasion , etc . ) facial area within 8 week baseline visit . Use topical retinoids related agent treatment acne photoaging precede 6 month . Any dermatological disorder , investigator 's opinion , may interfere accurate evaluation subject 's facial appearance . Has know sensitivity allergy cosmetic , soap , fragrance , ingredient test product . Is currently go menopause experience hot flash . Received investigational drug within 30 day study day 0 schedule receive investigational drug study product study . Currently use medication , opinion investigator may affect evaluation study product place subject undue risk ( include limit asthma medication , oral steroid , rifampin , anticonvulsant , St. John 's wart ) . Currently take topical oral erythromycincontaining product . History regional enteritis , ulcerative colitis , antibioticassociated colitis . Currently suffer disease condition , opinion investigator may affect evaluation study product place subject undue risk . Live household currently enrol subject . Employees investigator/ clinical research organization ( CRO ) Stiefel , GSK Company involve study , immediate family member ( partner , offspring , parent , sibling sibling 's offspring ) employee involve study . Any condition factor investigator duly assign representative believe may affect skin response interpretation test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>